Avantax Planning Partners, Inc. Lantern Pharma Inc. Transaction History
Avantax Planning Partners, Inc.
- $2.78 Billion
- Q3 2024
A detailed history of Avantax Planning Partners, Inc. transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Avantax Planning Partners, Inc. holds 11,640 shares of LTRN stock, worth $42,136. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,640
Previous 11,640
-0.0%
Holding current value
$42,136
Previous $54,000
22.22%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding LTRN
# of Institutions
33Shares Held
1.31MCall Options Held
39.8KPut Options Held
6.1K-
Vanguard Group Inc Valley Forge, PA364KShares$1.32 Million0.0% of portfolio
-
Cm Management, LLC185KShares$669,7000.57% of portfolio
-
New Edge Advisors, LLC New Orleans, LA137KShares$497,1630.0% of portfolio
-
Geode Capital Management, LLC Boston, MA87.4KShares$316,5140.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny84KShares$304,0800.0% of portfolio
About Lantern Pharma Inc.
- Ticker LTRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,830,900
- Market Cap $39.2M
- Description
- Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...